Distinct Mechanisms of Loss of IFN-gamma Mediated HLA Class I Inducibility in Two Melanoma Cell Lines
Overview
Authors
Affiliations
Background: The inability of cancer cells to present antigen on the cell surface via MHC class I molecules is one of the mechanisms by which tumor cells evade anti-tumor immunity. Alterations of Jak-STAT components of interferon (IFN)-mediated signaling can contribute to the mechanism of cell resistance to IFN, leading to lack of MHC class I inducibility. Hence, the identification of IFN-gamma-resistant tumors may have prognostic and/or therapeutic relevance. In the present study, we investigated a mechanism of MHC class I inducibility in response to IFN-gamma treatment in human melanoma cell lines.
Methods: Basal and IFN-induced expression of HLA class I antigens was analyzed by means of indirect immunofluorescence flow cytometry, Western Blot, RT-PCR, and quantitative real-time RT-PCR (TaqMan(R) Gene Expression Assays). In demethylation studies cells were cultured with 5-aza-2'-deoxycytidine. Electrophoretic Mobility Shift Assay (EMSA) was used to assay whether IRF-1 promoter binding activity is induced in IFN-gamma-treated cells.
Results: Altered IFN-gamma mediated HLA-class I induction was observed in two melanoma cells lines (ESTDAB-004 and ESTDAB-159) out of 57 studied, while treatment of these two cell lines with IFN-alpha led to normal induction of HLA class I antigen expression. Examination of STAT-1 in ESTDAB-004 after IFN-gamma treatment demonstrated that the STAT-1 protein was expressed but not phosphorylated. Interestingly, IFN-alpha treatment induced normal STAT-1 phosphorylation and HLA class I expression. In contrast, the absence of response to IFN-gamma in ESTDAB-159 was found to be associated with alterations in downstream components of the IFN-gamma signaling pathway.
Conclusion: We observed two distinct mechanisms of loss of IFN-gamma inducibility of HLA class I antigens in two melanoma cell lines. Our findings suggest that loss of HLA class I induction in ESTDAB-004 cells results from a defect in the earliest steps of the IFN-gamma signaling pathway due to absence of STAT-1 tyrosine-phosphorylation, while absence of IFN-gamma-mediated HLA class I expression in ESTDAB-159 cells is due to epigenetic blocking of IFN-regulatory factor 1 (IRF-1) transactivation.
Vizkeleti L, Papp O, Doma V, Gil J, Marko-Varga G, Kovacs S Sci Rep. 2024; 14(1):26540.
PMID: 39489756 PMC: 11532416. DOI: 10.1038/s41598-024-77285-x.
Ouyang Y, Gu Y, Zhang X, Huang Y, Wei X, Tang F BMC Cancer. 2024; 24(1):276.
PMID: 38424484 PMC: 10905944. DOI: 10.1186/s12885-024-12025-y.
Modification of the tumor microenvironment enhances immunity with plasmid gene therapy.
Shi G, Synowiec J, Singh J, Heller R Cancer Gene Ther. 2024; 31(4):641-648.
PMID: 38337037 PMC: 11702831. DOI: 10.1038/s41417-024-00728-0.
Strategies to overcome low MHC-I expression in paediatric and adult tumours.
Guillaume J, Perzolli A, Boes M Immunother Adv. 2024; 4(1):ltad028.
PMID: 38223409 PMC: 10787372. DOI: 10.1093/immadv/ltad028.
Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma.
Trojan A, Lone Y, Briceno I, Trojan J Curr Med Chem. 2023; 31(15):1983-2002.
PMID: 38031775 DOI: 10.2174/0109298673237968231106095141.